carboxyamidotriazole in treating patients with refractory or recurrent ovarian epithelial, fallopian tube, or primary peritoneal cancer

Conditions: Fallopian Tube Cancer; Ovarian Cancer; Primary Peritoneal Cavity Cancer

Summary: rationale: drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. purpose: phase ii trial to study the effectiveness of carboxyamidotriazole in treating patients with refractory or recurrent ovarian epithelial, fallopian tube, or primary peritoneal cancer.

objectives: * determine the clinical outcome in patients with ovarian epithelial, fallopian tube, or primary peritoneal cancer treated with carboxyamidotriazole. outline: patients receive oral carboxyamidotriazole daily beginning on day 1. treatment continues in the absence of disease progression or unacceptable toxicity. projected accrual: a total of 19-40 patients will be accrued for this study within 2 years.

Eligibility criteria:
disease characteristics: * histologically confirmed refractory or recurrent ovarian epithelial, fallopian tube, or primary peritoneal cancer * measurable disease by physical exam, radiography, peritoneoscopy, or laparoscopy * no more than 4 weeks since prior peritoneoscopy * no brain metastases patient characteristics: age: * 18 and over performance status: * ecog 0-2 life expectancy: * at least 4 months hematopoietic: * absolute neutrophil count at least 1,000/mm\^3 * platelet count at least 100,000/mm\^3 * hemoglobin at least 9.0 g/dl and/or * hematocrit at least 27% hepatic: * sgot/sgpt no greater than 3 times upper limit of normal * bilirubin normal renal: * creatinine no greater than 1.5 mg/dl or * creatinine clearance at least 50 ml/min cardiovascular: * no history of symptomatic cardiac dysrhythmias requiring medication * at least 6 months since prior myocardial infarction * no unstable or newly diagnosed angina pulmonary: * no obstructive lung disease requiring oxygen therapy other: * not pregnant or nursing * hiv negative * must be able to take oral medication * no concurrent medical condition (e.g., impending bowel obstruction) * no grade 2 or greater residual peripheral neuropathy * no active infection * no other prior or concurrent invasive malignancy within the past 5 years * no history of acute visual loss other than that associated with retinal detachment prior concurrent therapy: biologic therapy: * at least 4 weeks since prior cytokine therapy * no concurrent cytokine therapy to maintain wbc count chemotherapy: * at least 4 weeks since prior chemotherapy (6 weeks for nitrosoureas, carboplatin, or mitomycin) * no other concurrent chemotherapy endocrine therapy: * at least 4 weeks since prior hormonal therapy * no concurrent corticosteroids at doses greater than physiological replacement doses * no concurrent hormonal therapy radiotherapy: * at least 4 weeks since prior radiotherapy * no concurrent radiotherapy surgery: * see disease characteristics other: * no more than 3 prior treatment regimens * at least 1 week since prior systemic antibiotics for infection * no chronic antifungal treatment with antimycotic imidazoles * no concurrent alternative therapies

Keywords: recurrent ovarian epithelial cancer fallopian tube cancer primary peritoneal cavity cancer